Thelansis

Progressive Familial Intrahepatic Cholestasis (PFIC) Market Outlook Thelansis’s “Progressive Familial Intrahepatic Cholestasis (PFIC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Progressive Familial Intrahepatic Cholestasis (PFIC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and ...

Progressive Familial Intrahepatic Cholestasis (PFIC) Market Outlook Thelansis’s “Progressive Familial Intrahepatic Cholestasis (PFIC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Progressive Familial Intrahepatic Cholestasis (PFIC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Progressive Familial Intrahepatic Cholestasis (PFIC) Overview Progressive familial intrahepatic cholestasis (PFIC) is an inherited liver condition that hinders bile drainage despite open large bile ducts, leading to cholestasis. It typically presents in early childhood with pruritus, dark urine, pale stool, decreased appetite, and fatigue. PFIC is c...

 Progressive familial intrahepatic cholestasis (PFIC) is an inherited liver condition that hinders bile drainage despite open large bile ducts, leading to cholestasis. It typically presents in early childhood with pruritus, dark urine, pale stool, decreased appetite, and fatigue. PFIC is categorized into three subtypes: PFIC type 1, PFIC type 2, and PFIC type 3, each linked to mutations in the ATP8B1, ABCB11, and ABCB4 genes, respectively. However, some PFIC cases lack these specific gene mutations. Signs and symptoms encompass severe itching (pruritus), inadequate weight gain due to impaired fat digestion and absorption, jaundice (skin yellowing), bleeding due to vitamin K deficiency, and poor bone growth from vitamin D deficiency. Various treatment options, both medical and surgical, are available. The primary medical treatment for all PFIC variants is ursodeoxycholic acid (UDCA). Nevertheless, most PFIC patients develop end-stage liver disease with significant fibrosis in adulth...

  Progressive familial intrahepatic cholestasis (PFIC) is inherited condition that affects the liver. In PFIC, children are not able to drain bile from the liver even though the large bile ducts are open (cholestasis). Mutations in the ATP8B1, ABCB11, and ABCB4 genes cause PFIC1, PFIC2 and PFIC3, respectively. Some people with PFIC do not have a mutation in the ATP8B1, ABCB11, or ABCB4 gene. PFIC is estimated to affect 1 in 50,000 to 100,000 people worldwide. PFIC type 1 is much more common in the Inuit population of Greenland and the Old Order Amish population of the United States. Thelansis’s “Progressive Familial Intrahepatic Cholestasis (PFIC) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights ...